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New-onset	 atrial	 fibrillation	 (AF)	 is	 the	 most	 common	 arrhythmia	 in	 critically	 ill	25	
patients.	Although	evidence	base	and	expert	consensus	opinion	for	management	have	26	
been	 summarised	 in	 several	 international	 guidelines,	 no	 specific	 considerations	 for	27	















onset	 fast	 AF,	 while	 30.8%	 anti-coagulate	 within	 72	 hours.	 68.0%	 of	 survey	43	
respondents	do	not	routinely	use	stroke	risk	scores	in	critically	ill	patients	with	new-44	
onset	AF.		45	
85.4%	 of	 participants	 would	 consider	 taking	 part	 in	 a	 clinical	 trial	 investigating	46	
treatment	of	new-onset	fast	AF	in	the	critically	ill.	47	
Discussion:	48	
Our	 results	 suggest	 a	 considerable	 disparity	 between	 contemporary	 practice	 of	49	
management	of	new-onset	AF	in	critical	illness	and	treatment	recommendations	for	50	
the	 general	 patient	 population	 suffering	 from	 AF,	 particularly	 with	 regard	 to	 anti-51	









- Identification	of	 a	 research	 interest	 in	 practising	 intensivists	 to	 address	 new	59	
onset	atrial	fibrillation	as	a	common	clinical	problem	in	acutely	ill	patients	60	






- The	 survey	was	 aimed	 at	 general	 intensivists	without	 specifically	 addressing	67	




















factors	 and	 outcomes	 of	 new-onset	 atrial	 fibrillation	 in	 critical	 care,	 while	 little	88	






























questions,	 which	 were	 divided	 into	 two	 domains.	 The	 first	 domain	 comprised	 7	117	




Demographic	 variables	 included	 type	of	 practice	 hospitals	 (district	 general,	 tertiary	122	
referral	centre	or	university	hospital),	the	number	of	patients	admitted	to	the	unit	per	123	




level	 of	 training,	 years	 of	 experience	 and	 any	 secondary	 specialty	 of	 the	 survey	126	
participants.		127	
To	identify	and	explore	the	current	practice	in	managing	critically	ill	patients	with	new-128	
onset	 AF,	 participants	 were	 asked	 to	 state	 a	 threshold	 heart	 rate	 at	 which	 they	129	





survey	 question,	 participants	were	 given	 options	 of	 different	 treatment	 strategies,	135	
including	 electrolyte	 supplementation,	 Direct	 Current	 (DC)	 cardioversion	 and	 anti-136	
arrhythmic	 drugs.	 Survey	 participants	 were	 requested	 to	 state	 their	 target	 serum	137	
potassium	and	serum	magnesium	level	among	critical	care	patients	with	new-onset	138	
AF.		139	
Finally,	 participants	were	also	asked	about	 their	 anti-coagulation	practice	 including	140	
duration	and	medication	used	and	their	views	on	stroke	risk	assessments	in	critically	141	
ill	 patients	 with	 new-onset	 AF.	 A	 further	 question	 explored	 the	 use	 of	 trans-142	
oesophageal	or	transthoracic	echocardiography	to	guide	treatment.	At	the	end	of	the	143	
survey,	their	views	on	conducting	a	clinical	trial	investigating	treatment	of	new-onset	144	
AF	 in	 this	 subgroup	 of	 patients	 were	 obtained.	 This	 included	 the	 anti-arrhythmic	145	
medications	at	highest	priority	for	investigation	and	acceptability	of	a	placebo	arm	in	146	





statistics	 were	 carried	 out	 by	 providing	 absolute	 numbers	 and	 percentages	 of	152	
background	and	demographic	variables	and	 for	all	questions	 relating	 to	knowledge	153	
and	 current	 practice.	 Where	 applicable,	 contingency	 tables	 were	 produced	 and	154	
analysed	using	Fisher’s	exact	test.	To	measure	of	association	between	two	nominal	155	









had	 been	 opened	without	 provision	 of	 replies	were	 excluded	 from	 the	 study.	 397	163	




46.6%	 of	 respondents	 were	 from	 District	 General	 Hospitals;	 a	 smaller	 proportion	168	
(38.5%)	worked	in	University	Hospitals	or	Tertiary	referral	centres.	The	admission	rate	169	
ranged	between	500	 and	2000	patients/year	 in	most	 centres,	 81.1%	of	 units	were	170	
mixed	ICUs	admitting	medical	and	surgical	patients	(Table	1).	171	
Most	respondents	(47.2%)	worked	on	units	with	11-20	staffed	beds	(level	2	and	level	172	







similar	 proportion	 of	 respondents	 (34.8%)	would	 treat	 all	 patients	who	 developed	180	
















of	 100/60	 mmHg	 and	 received	 0.25	 mcg/kg/min	 noradrenaline.	 Most	 survey	197	
respondents	 opted	 for	 electrolyte	 supplementation	 to	 high	 normal	 level	 and	198	
7	
	
additional	 anti-arrhythmics	 (53.6%).	 23.8%	 of	 respondents	 advocated	 electrolyte	199	
supplementation	to	a	high	normal	level	only,	and	14.9%	opted	for	DC	cardioversion	200	
when	anti-arrhythmics	and	electrolyte	replacement	fail	to	achieve	rate	and/or	rhythm	201	










weight	 heparin	 in	 therapeutic	 dose	 is	 appropriate	 for	 anti-coagulation	 and	 26,8%	212	
considered	intravenous	high	molecular	weight	heparin	as	appropriate,	provided	that	213	
no	 contra-	 indications	 for	 either	 substance	 were	 known	 (Table	 3b).	 Sub-analysis	214	
excluding	respondents	who	gave	“I	do	not	regularly	anti-coagulate	critically	ill	patients	215	
with	 new	 onset	 fast	 AF”	 as	 the	 only	 answer	 (136/362	 respondents),	 revealed	 that	216	
either	 low	 or	 high	molecular	 weight	 heparin	 was	 considered	 appropriate	 for	 anti-217	
coagulation	by	more	than	98%	of	physicians.	218	
68.0%	of	 survey	 respondents	did	not	use	 stroke	 risk	 scores	 routinely	 in	 critically	 ill	219	
patients	with	new-onset	AF	to	assess	the	need	for	anticoagulation.	30.9%	of	survey	220	
respondents	 thought	 that	 stroke	 risk	 scores	 inaccurately	 reflect	 the	 risk	of	embolic	221	
events	in	critically	ill	patients	with	new-onset	atrial	fibrillation	due	to	prothrombotic	222	
changes	associated	with	critical	illness.	47.0%	of	respondents	thought	that	modified	223	




echocardiography,	 while	 a	 large	 proportion	 (48.9%)	 would	 request	 a	 transthoracic	228	










placebo	 arm	 (i.e.	 not	 treating	 new-onset	 AF	 with	 anti-arrhythmics	 or	 rate-limiting	237	





















independent	 of	 their	 heart	 rate,	 even	 if	 the	 blood	 pressure	 remained	 stable,	259	





single-center,	 retrospective,	 cohort	 study	 described	 a	 higher	 mortality	 in	 septic	265	
patients	with	new-onset	AF	who	failed	to	convert	into	sinus	rhythm	(Liu	et	al.	2016).	266	
Rhythm	control	and	rate	control	have	both	been	used	as	outcome	measures	in	the	few	267	






was	 a	 randomised	 controlled	 trial.	 Therapies	 studied	 to	 date	 include	beta-blockers	274	






2008),	 Sotalol	 (Kanji	 et	 al.	 2008)	 and	digitalis	 glycosides	 (Meierhenrich	 et	 al.	 2010;	279	
Seguin	et	al.	2006).	The	need	to	perform	research	on	treatment	of	new-onset	AF	in	280	
















factors	 for	 new-onset	AF	 in	 the	 critically	 ill	 include	 inotropic	 support	 (Seguin	 et	 al.	297	
2006),	advanced	age	and	high	scores	of	severity	of	disease	(Yoshida	et	al.	2015).	In	the	298	
United	Stated,	where	diltiazem	 is	available	 for	 intravenous	administration,	calcium-299	
channel	blockers	were	the	most	frequently	used	drugs	to	treat	new-onset	AF	during	300	





sulphate	 bolus	 application	 followed	by	 continuous	 infusion	 achieved	 conversion	 to	306	
sinus	rhythm	or	decrease	in	heart	rate	<110	bpm	in	16	of	29	patients	(55%)	in	a	small	307	
prospective	 study	 (Sleeswijk	 et	 al.	 2008),	 while	 magnesium-amiodarone	 step-up	308	
therapy	achieved	a	conversion	rate	of	more	than	90%	within	24	h	in	a	cohort	of	mixed	309	
critically	 ill	 patients.	 Although	 these	 findings	 suggest	 that	 amiodarone,	magnesium	310	
sulphate,	or	the	combination	thereof	might	be	effective	to	prevent	or	treat	new-onset	311	









request	 a	 transthoracic	 echo,	 a	 large	 proportion	 (39%)	 does	 not	 routinely	 use	319	
echocardiography	to	guide	management	in	this	patient	cohort.	320	
	321	
NICE/ACC/AHA/ESC	 practice	 guidelines	 recommend	 routine	 anti-coagulation	 of	322	
patients	 with	 new-onset	 AF	 depending	 on	 their	 individual	 risk	 of	 thromboembolic	323	
events	 using	 established	 scores	 such	 as	 CHADS2	 and	 CHA2DS2-VASc	 (Jones	 et	 al.	324	
2014).	However,	the	risk	of	stroke	and	thromboembolic	events	in	critically	ill	patients	325	
who	 develop	 new-onset	 AF	 has	 been	 evaluated	 in	 only	 very	 few	 studies.	 A	 recent	326	
prospective	observational	study	revealed	that	both	CHADS2	and	CHA2DS2-VASc	are	327	
predictive	of	thromboembolic	events	in	the	critical	care	setting	(Champion	et	al.	2014),	328	
with	 a	 CHADS2	 score	 of	 4	 or	 higher	 being	 the	most	 accurate	 threshold.	 In	 a	 large	329	
retrospective	study	on	more	than	49	000	patients	with	sepsis	Walkey	et	al	(Walkey	et	330	









due	 to	 thrombocytopenia,	 renal	 failure,	 liver	 failure,	 invasive	 devices,	 and	340	
unscheduled	 procedures	 (Walkey	 et	 al.	 2015),	 and	 bleeding	 complications	 such	 as	341	





















stroke.	 A	 proposed	 approach	 to	 long-term	 management	 of	 patients	 who	 develop	361	
periods	of	AF	during	critical	illness	includes	re-assessment	for	rhythm	and	heart	rate	362	
surveillance,	 cardiovascular	 comorbidities,	 thyroid	 function,	 stroke	 risk	 and	 should	363	
include	echocardiography	and	patients’	preferences	(Walkey	et	al.	2015)	to	manage	364	
stroke	 and	 cardiovascular	 risk	 after	 ICU	 discharge.	 However,	 data	 are	 lacking	 to	365	
estimate	 rates	 of	 severe	 bleeding	 versus	 stroke	 risk	 with	 use	 of	 systemic	366	












number	 of	 general	 questions	 only	 to	 allow	 rapid	 completion.	Hence,	we	 could	 not	379	
thoroughly	explore	background	knowledge	and	experience	of	the	respondents	 in	 in	380	
this	complex	 field.	 In	particular,	 treatment	strategies	 in	 relation	to	cardiac	 function	381	
and	 combination	 of	 therapies	 such	 as	 cardioversion	 in	 addition	 to	 anti-arrhythmic	382	
substances	could	not	be	evaluated.		383	
Our	survey	focused	on	general	management	of	new-onset	atrial	fibrillation	in	critical	384	
care;	 specific	 subgroups	 of	 patients	 including	 those	 after	 cardiothoracic	 surgery	 or	385	
with	primary	cardiac	diagnoses	were	not	specifically	addressed.	These	patient	cohorts	386	


















providing	 data	 about	 ICS	 and	 FICM	 membership.	 We	 would	 also	 like	 to	 thank	 all	403	
members	of	the	Intensive	Care	Society	who	took	the	time	to	respond	to	the	survey	404	
invitation.	405	
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Legends	to	Figures	and	Tables	518	
	519	
Tables:	520	
Table	1:		Intensive	Care	Unit	(ICU)	characteristics	and	level	of	Level	of	training	of	521	
survey	respondents.	SAS	=	Specialty	and	associate	specialist	(Doctors	not	in	training	522	
with	at	least	four	years	postgraduate	experience).	523	
Table	2:	Survey	responses	regarding	heart	rate	at	which	doctors	would	intervene	524	
depending	on	their	primary	treatment	goal	(rate	versus	rhythm	control).		525	
Table	3:		Survey	responses	regarding	initiation	of	anticoagulation	treatment	in	atrial	526	
fibrillation	and	choice	of	appropriate	anticoagulants.	527	
Table	4:	Survey	responses	regarding	stroke	risk	assessment	in	critically	ill	patients	528	
with	new-onset	atrial	fibrillation		529	
	530	
Figures:	531	
Figure	1:	Medications	used	for	treatment	of	new-onset	atrial	fibrillation		532	
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